CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 25.17M | 13.39M | 4.10M | 3.51M | 38.34M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.17M | 13.39M | 4.10M | 3.51M | 38.34M |
| Cost of Revenue | 472.35M | 475.19M | 482.82M | 498.29M | 443.21M |
| Gross Profit | -447.18M | -461.80M | -478.71M | -494.78M | -404.88M |
| SG&A Expenses | 71.00M | 70.07M | 71.43M | 73.54M | 73.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 543.35M | 545.26M | 554.25M | 571.83M | 516.48M |
| Operating Income | -518.18M | -531.87M | -550.14M | -568.32M | -478.14M |
| Income Before Tax | -453.65M | -448.11M | -565.17M | -577.97M | -484.58M |
| Income Tax Expenses | 2.49M | 3.03M | 3.36M | 3.63M | 3.72M |
| Earnings from Continuing Operations | -456.14 | -451.14 | -568.53 | -581.60 | -488.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -456.14M | -451.14M | -568.53M | -581.60M | -488.30M |
| EBIT | -518.18M | -531.87M | -550.14M | -568.32M | -478.14M |
| EBITDA | -499.68M | -513.17M | -531.08M | -548.84M | -459.48M |
| EPS Basic | -4.75 | -4.76 | -6.21 | -6.51 | -5.58 |
| Normalized Basic EPS | -2.86 | -2.94 | -3.17 | -3.36 | -2.77 |
| EPS Diluted | -4.75 | -4.77 | -6.22 | -6.52 | -5.59 |
| Normalized Diluted EPS | -2.86 | -2.94 | -3.17 | -3.36 | -2.77 |
| Average Basic Shares Outstanding | 384.58M | 379.14M | 369.70M | 359.58M | 349.78M |
| Average Diluted Shares Outstanding | 384.58M | 379.14M | 369.70M | 359.58M | 349.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |